Form 4: Alector CFO Granted 54,600 Restricted Stock Units

Alector, Inc.'s CFO and Chief Business Officer, Neil Lindsay Berkley, was granted 54,600 restricted stock units.

Summary

• Neil Lindsay Berkley, the Chief Financial Officer and Chief Business Officer of Alector, Inc., acquired 54,600 shares of common stock.
• The acquisition occurred on March 15, 2026, and was in the form of Restricted Stock Units (RSUs) with an acquisition price of $0 per share.
• These RSUs are scheduled to vest in two equal tranches: 27,300 shares on September 1, 2026, and the remaining 27,300 shares on March 1, 2027.
• Following this transaction, Neil Lindsay Berkley beneficially owns a total of 399,260 shares of Alector, Inc. common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive alignment with shareholder interests through equity compensation and a commitment to the company's future, without indicating any immediate operational changes.

Positives

• The grant of restricted stock units to a key executive like the CFO and CBO aligns management's long-term interests with those of shareholders.
• The multi-year vesting schedule for the RSUs acts as a retention incentive, encouraging the executive to remain with the company and contribute to its sustained performance.

Negatives

• The transaction was a grant of RSUs rather than an open market purchase, which would typically signal a stronger conviction in the company's immediate stock price by the insider.

Risks

• The ultimate value of the granted RSUs is directly dependent on Alector, Inc.'s future stock price performance, exposing the executive to market volatility.
• Future stock price performance is subject to various company-specific factors, including clinical trial results, regulatory approvals, and commercialization success, as well as broader market and industry risks.

Future Outlook

The vesting schedule for the granted RSUs extends into March 2027, indicating a continued commitment from the executive to the company's long-term performance and strategic objectives.

Industry Context

StockSavvy.ai notes that RSU grants are a prevalent form of executive compensation within the biotechnology and pharmaceutical sectors. This practice is designed to align executive incentives with long-term company growth and shareholder value creation, which is particularly crucial given the extended research and development cycles inherent in drug discovery and commercialization.

Comparison to Industry Standards

• The grant of RSUs to a CFO/CBO is a standard component of executive compensation packages in the biotech industry, comparable to practices observed at peer companies such as Biogen Inc. or Gilead Sciences, Inc., where equity awards form a significant portion of total executive remuneration.
• The vesting schedule, spanning approximately one year with two tranches, is typical for retention and performance-based incentives, aligning with common industry practices for annual equity grants among publicly traded life sciences companies.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CFO's financial interests with the long-term performance of the company, potentially encouraging decisions that enhance shareholder value.
• Employees: Standard executive compensation practices, including equity grants, can contribute to a positive corporate culture and serve as a benchmark for broader employee incentive programs.

Next Steps

• First tranche of 27,300 RSUs to vest on September 1, 2026.
• Second tranche of 27,300 RSUs to vest on March 1, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock units to a key executive, which is a standard component of executive compensation. While it indicates continued executive alignment and retention, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Alector, ALEC, Form 4, Insider Transaction, Restricted Stock Units, RSU, Executive Compensation, CFO, Neil Lindsay Berkley, Biotechnology, Pharmaceuticals